- Home
- ASH vs GLPG Comparison
ASH vs GLPG Comparison
Compare ASH & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASH
- GLPG
- Stock Information
- Founded
- ASH 1924
- GLPG 1999
- Country
- ASH United States
- GLPG Belgium
- Employees
- ASH N/A
- GLPG N/A
- Industry
- ASH Specialty Chemicals
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- ASH Consumer Discretionary
- GLPG Health Care
- Exchange
- ASH Nasdaq
- GLPG Nasdaq
- Market Cap
- ASH 2.3B
- GLPG 1.9B
- IPO Year
- ASH N/A
- GLPG 2005
- Fundamental
- Price
- ASH $53.39
- GLPG $30.32
- Analyst Decision
- ASH Buy
- GLPG Sell
- Analyst Count
- ASH 5
- GLPG 4
- Target Price
- ASH $70.50
- GLPG $25.33
- AVG Volume (30 Days)
- ASH 553.6K
- GLPG 240.0K
- Earning Date
- ASH 08-05-2025
- GLPG 07-23-2025
- Dividend Yield
- ASH 3.05%
- GLPG N/A
- EPS Growth
- ASH N/A
- GLPG N/A
- EPS
- ASH N/A
- GLPG N/A
- Revenue
- ASH $1,949,000,000.00
- GLPG $311,493,731.00
- Revenue This Year
- ASH N/A
- GLPG $0.78
- Revenue Next Year
- ASH $2.35
- GLPG N/A
- P/E Ratio
- ASH N/A
- GLPG N/A
- Revenue Growth
- ASH N/A
- GLPG 18.32
- 52 Week Low
- ASH $45.21
- GLPG $22.36
- 52 Week High
- ASH $98.44
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- ASH 56.60
- GLPG 67.62
- Support Level
- ASH $52.34
- GLPG $28.21
- Resistance Level
- ASH $55.44
- GLPG $30.64
- Average True Range (ATR)
- ASH 1.56
- GLPG 0.52
- MACD
- ASH 0.35
- GLPG 0.23
- Stochastic Oscillator
- ASH 70.80
- GLPG 91.29
About ASH Ashland Inc.
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.